骨髓保护性调强放疗联合同步顺铂治疗IB-IVA期宫颈癌:国际多中心II期临床试验(INTERTECC-2)
该单臂II期试验纳入83例IB-IVA期宫颈癌患者,接受每周顺铂同步每日一次IMRT及腔内近距离放疗。主要终点(急性≥3级中性粒细胞减少或临床显著胃肠道毒性)发生率为26.5%(95%CI 18.2%-36.9%),显著低于历史假设的40%(P=.012)。基于PET的图像引导IMRT(IG-IMRT)较非IG-IMRT显著降低≥3级中性粒细胞减少发生率(8.6% vs 27.1%,P=.035)。
要点
- IMRT同步顺铂的急性≥3级中性粒细胞减少或临床显著胃肠道毒性发生率为26.5%,低于历史40%假设。
- 基于PET的IG-IMRT组≥3级中性粒细胞减少发生率8.6%,显著低于非IG-IMRT组的27.1%。
- ≥3级中性粒细胞减少和临床显著胃肠道毒性发生率分别为19.3%和12.0%。
核心结论
- IMRT较标准治疗降低急性血液学和胃肠道毒性,且治疗结局有前景。
- 基于PET的IG-IMRT降低急性中性粒细胞减少的发生率。
研究设计与样本
- 所有患者接受每周顺铂同步每日一次IMRT,后续按指征行腔内近距离放疗。
- 主要终点为完成放化疗后30天内发生急性≥3级中性粒细胞减少或临床显著胃肠道毒性。
- 预设亚组分析检验基于PET的IG-IMRT降低急性中性粒细胞减少风险的假设。
- 中位随访26.0个月,并纵向评估生活质量变化。
主要发现
- 主要终点事件发生率为26.5%(95%CI 18.2%-36.9%),显著低于历史数据假设的40%(P=.012)。
- ≥3级中性粒细胞减少发生率为19.3%(95%CI 12.2%-29.0%)。
- 临床显著胃肠道毒性发生率为12.0%(95%CI 6.7%-20.8%)。
- IG-IMRT组(n=35)较非IG-IMRT组(n=48)≥3级中性粒细胞减少发生率显著更低(8.6% vs 27.1%;双侧χ2 P=.035)。
- IG-IMRT组≥3级白细胞减少(25.7% vs 41.7%;P=.13)和任何≥3级血液学毒性(31.4% vs 43.8%;P=.25)发生率数值更低但未达统计学显著。
关键数值与推荐
- 主要终点事件发生率26.5%(95%CI 18.2%-36.9%),显著低于预设的40%(P=.012)。
- ≥3级中性粒细胞减少发生率19.3%(95%CI 12.2%-29.0%),临床显著胃肠道毒性发生率12.0%(95%CI 6.7%-20.8%)。
- IG-IMRT组与非IG-IMRT组≥3级中性粒细胞减少发生率分别为8.6%与27.1%(P=.035)。
临床怎么用
- 对IB-IVA期宫颈癌行同步顺铂放化疗时,采用IMRT可降低急性血液学和胃肠道毒性。
- 基于PET的IG-IMRT有助于进一步降低急性中性粒细胞减少风险。
局限性
- 本研究为单臂II期试验,未设随机对照。
- IG-IMRT与非IG-IMRT的比较为预设亚组分析,非随机分组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To test the hypothesis that intensity modulated radiation therapy (IMRT) reduces acute hematologic and gastrointestinal (GI) toxicity for patients with locoregionally advanced cervical cancer. METHODS AND MATERIALS: We enrolled patients with stage IB-IVA cervical carcinoma in a single-arm phase II trial involving 8 centers internationally. All patients received weekly cisplatin concurrently with once-daily IMRT, followed by intracavitary brachytherapy, as indicated. The primary endpoint was the occurrence of either acute grade ≥3 neutropenia or clinically significant GI toxicity within 30 days of completing chemoradiation therapy. A preplanned subgroup analysis tested the hypothesis that positron emission tomography-based image-guided IMRT (IG-IMRT) would lower the risk of acute neutropenia. We also longitudinally assessed patients' changes in quality of life. RESULTS: From October 2011 to April 2015, 83 patients met the eligibility criteria and initiated protocol therapy. The median follow-up was 26.0 months. The incidence of any primary event was 26.5% (95% confidence interval [CI] 18.2%-36.9%), significantly lower than the 40% incidence hypothesized a priori from historical data (P=.012). The incidence of grade ≥3 neutropenia and clinically significant GI toxicity was 19.3% (95% CI 12.2%-29.0%) and 12.0% (95% CI 6.7%-20.8%), respectively. Compared with patients treated without IG-IMRT (n=48), those treated with IG-IMRT (n=35) had a significantly lower incidence of grade ≥3 neutropenia (8.6% vs 27.1%; 2-sided χ2P=.035) and nonsignificantly lower incidence of grade ≥3 leukopenia (25.7% vs 41.7%; P=.13) and any grade ≥3 hematologic toxicity (31.4% vs 43.8%; P=.25). CONCLUSIONS: IMRT reduces acute hematologic and GI toxicity compared with standard treatment, with promising therapeutic outcomes. Positron emission tomography IG-IMRT reduces the incidence of acute neutropenia.
引用
- Mell LK, Sirák I, Wei L, et al. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2). Int J Radiat Oncol Biol Phys. 2016. PMID: 28126303. doi:10.1016/j.ijrobp.2016.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。